FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023588049> ?p ?o ?g. }

• W2023588049 endingPage "101" @default.
• W2023588049 startingPage "95" @default.
• W2023588049 abstract "Background Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency. Pegfilgrastim is indicated to decrease infection as manifested by febrile neutropenia (FN) in patients receiving chemotherapy at > 14-day intervals. This randomized, placebo-controlled phase II study examined pegfilgrastim efficacy and safety in patients with CRC receiving every-2-week chemotherapy. Patients and Methods Patients with CRC were randomized 1:1 to pegfilgrastim 6 mg or placebo administered per-cycle on day 4. Randomization was stratified by chemotherapy regimen (patients received every-2-week FOLFOX4 [5-FU/LV/oxaliplatin], FOLFIRI [5-FU/LV/irinotecan], or FOIL [5-FU/LV/oxaliplatin/irinotecan] at physician discretion). The primary endpoint was incidence of grade 3/4 neutropenia. Secondary endpoints included incidence of grade 3/4 FN and adverse events. After 4 cycles of study treatment, progression-free survival (PFS) and overall survival (OS) were followed for ≤ 2 years in long-term follow-up. Results Of 241 eligible patients analyzed, 118 were in the placebo and 123 in the pegfilgrastim group. In the treatment period, the odds ratio for grade 3/4 neutropenia for pegfilgrastim versus placebo was 0.19 (95% CI, 0.10-0.37; P < .001); grade 3/4 FN incidence was also significantly lower in pegfilgrastim-treated patients (2%) compared with placebo-treated patients (8%; P = .04). Pegfilgrastim was well tolerated, with leukocyte counts remaining stable during cycles 2-4. In long-term follow-up, both treatment groups had similar PFS and OS. Conclusion Pegfilgrastim was well tolerated in patients with CRC receiving every-2-week chemotherapy and significantly reduced neutropenia and FN compared with placebo, though FN was uncommon in both treatment groups. Results suggest that pegfilgrastim administration is feasible in CRC patients receiving every-2-week chemotherapy." @default.
• W2023588049 created "2016-06-24" @default.
• W2023588049 creator A5001297197 @default.
• W2023588049 creator A5010412874 @default.
• W2023588049 creator A5043765880 @default.
• W2023588049 creator A5043930952 @default.
• W2023588049 creator A5047556737 @default.
• W2023588049 creator A5068275318 @default.
• W2023588049 creator A5071328253 @default.
• W2023588049 creator A5072401254 @default.
• W2023588049 creator A5077135968 @default.
• W2023588049 date "2010-04-01" @default.
• W2023588049 modified "2023-10-16" @default.
• W2023588049 title "A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy" @default.
• W2023588049 cites W1965734230 @default.
• W2023588049 cites W1986748792 @default.
• W2023588049 cites W2024933507 @default.
• W2023588049 cites W2033992465 @default.
• W2023588049 cites W2036450045 @default.
• W2023588049 cites W2051224942 @default.
• W2023588049 cites W2083336892 @default.
• W2023588049 cites W2121368761 @default.
• W2023588049 cites W2128447158 @default.
• W2023588049 cites W2132738278 @default.
• W2023588049 cites W2146798192 @default.
• W2023588049 cites W2329974252 @default.
• W2023588049 cites W2993305496 @default.
• W2023588049 cites W2168123077 @default.
• W2023588049 doi "https://doi.org/10.3816/ccc.2010.n.013" @default.
• W2023588049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20378503" @default.
• W2023588049 hasPublicationYear "2010" @default.
• W2023588049 type Work @default.
• W2023588049 sameAs 2023588049 @default.
• W2023588049 citedByCount "53" @default.
• W2023588049 countsByYear W20235880492012 @default.
• W2023588049 countsByYear W20235880492013 @default.
• W2023588049 countsByYear W20235880492014 @default.
• W2023588049 countsByYear W20235880492015 @default.
• W2023588049 countsByYear W20235880492016 @default.
• W2023588049 countsByYear W20235880492017 @default.
• W2023588049 countsByYear W20235880492018 @default.
• W2023588049 countsByYear W20235880492019 @default.
• W2023588049 countsByYear W20235880492020 @default.
• W2023588049 countsByYear W20235880492021 @default.
• W2023588049 countsByYear W20235880492022 @default.
• W2023588049 crossrefType "journal-article" @default.
• W2023588049 hasAuthorship W2023588049A5001297197 @default.
• W2023588049 hasAuthorship W2023588049A5010412874 @default.
• W2023588049 hasAuthorship W2023588049A5043765880 @default.
• W2023588049 hasAuthorship W2023588049A5043930952 @default.
• W2023588049 hasAuthorship W2023588049A5047556737 @default.
• W2023588049 hasAuthorship W2023588049A5068275318 @default.
• W2023588049 hasAuthorship W2023588049A5071328253 @default.
• W2023588049 hasAuthorship W2023588049A5072401254 @default.
• W2023588049 hasAuthorship W2023588049A5077135968 @default.
• W2023588049 hasConcept C121608353 @default.
• W2023588049 hasConcept C126322002 @default.
• W2023588049 hasConcept C141071460 @default.
• W2023588049 hasConcept C142724271 @default.
• W2023588049 hasConcept C168563851 @default.
• W2023588049 hasConcept C203092338 @default.
• W2023588049 hasConcept C204787440 @default.
• W2023588049 hasConcept C27081682 @default.
• W2023588049 hasConcept C2776694085 @default.
• W2023588049 hasConcept C2777063308 @default.
• W2023588049 hasConcept C2778658803 @default.
• W2023588049 hasConcept C2778850193 @default.
• W2023588049 hasConcept C2779171977 @default.
• W2023588049 hasConcept C2780259306 @default.
• W2023588049 hasConcept C2780962732 @default.
• W2023588049 hasConcept C526805850 @default.
• W2023588049 hasConcept C71924100 @default.
• W2023588049 hasConcept C90924648 @default.
• W2023588049 hasConceptScore W2023588049C121608353 @default.
• W2023588049 hasConceptScore W2023588049C126322002 @default.
• W2023588049 hasConceptScore W2023588049C141071460 @default.
• W2023588049 hasConceptScore W2023588049C142724271 @default.
• W2023588049 hasConceptScore W2023588049C168563851 @default.
• W2023588049 hasConceptScore W2023588049C203092338 @default.
• W2023588049 hasConceptScore W2023588049C204787440 @default.
• W2023588049 hasConceptScore W2023588049C27081682 @default.
• W2023588049 hasConceptScore W2023588049C2776694085 @default.
• W2023588049 hasConceptScore W2023588049C2777063308 @default.
• W2023588049 hasConceptScore W2023588049C2778658803 @default.
• W2023588049 hasConceptScore W2023588049C2778850193 @default.
• W2023588049 hasConceptScore W2023588049C2779171977 @default.
• W2023588049 hasConceptScore W2023588049C2780259306 @default.
• W2023588049 hasConceptScore W2023588049C2780962732 @default.
• W2023588049 hasConceptScore W2023588049C526805850 @default.
• W2023588049 hasConceptScore W2023588049C71924100 @default.
• W2023588049 hasConceptScore W2023588049C90924648 @default.
• W2023588049 hasIssue "2" @default.
• W2023588049 hasLocation W20235880491 @default.
• W2023588049 hasLocation W20235880492 @default.
• W2023588049 hasOpenAccess W2023588049 @default.
• W2023588049 hasPrimaryLocation W20235880491 @default.
• W2023588049 hasRelatedWork W1638203718 @default.
• W2023588049 hasRelatedWork W180056525 @default.

• next